The New York-based law firm is currently investigating Element Solutions Inc. (ESI) regarding its sale to Solstice Advanced Materials, Inc., where shareholders stand to receive $10.00 in cash and 0.500 shares of Solstice stock. The firm is also examining the $85.00 per share cash deal between Crinetics Pharmaceuticals, Inc. (CRNX) and Vertex Pharmaceuticals Incorporated. A concurrent investigation targets the merger between Solstice Advanced Materials (SOLS) and Element Solutions.

Halper Sadeh attorneys are evaluating whether these transactions comply with federal securities laws or if they represent a failure of fiduciary duty. The firm suggests that current terms could limit shareholder value and is seeking potential remedies, including increased consideration or additional corporate disclosures. Shareholders involved in these companies are being invited to discuss their rights on a contingent fee basis, with no upfront costs for legal expenses.